CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Insulin glulisine

Last Updated: August 29, 2008
Result type: Reports
Project Number: SR0144-000
Product Line: Reimbursement Review

Generic Name: Insulin glulisine

Brand Name: Apidra

Manufacturer: Sanofi-Aventis Canada Inc.

Therapeutic Area: Diabetes, Mellitus (Type 1 & 2)

Indications: Diabetes, Mellitus (Type 1 & 2)

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: February 19, 2009

Recommendation Type: List in a similar manner to other drugs in class